Abstract
The field of multiple sclerosis (MS) therapeutics, particularly for relapsing-remitting MS (RRMS), is rapidly evolving. Many agents are currently in various stages of clinical trials, with several medications presently under regulatory review. New treatments for MS pose exciting opportunities for disease control of relapsing MS; however, new mechanisms of action carry the potential for new side effects, novel adverse events, and the need for vigilant monitoring to ensure their safe and effective use. This chapter will review several promising emerging MS therapies, with an emphasis on two agents that have completed Phase III studies (daclizumab and ocrelizumab), as well as new approaches of great interest to patients with MS: remyelination therapy and the potential use of stem cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Helliwell CL, Coles AJ. Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Ther Adv Neurol Disord. 2009;2:195–203.
Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–75.
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472–81.
Kappos L, Selmaj K, Arnold D, Boyko A, Kaufman M, Wiendl H, et al. Primary results of DECIDE: a randomized, double-blind, doubledummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients. Presented at ACTRIMS-ECTRIMS 2014; 10–13 Sept 2014; Boston.
Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–87.
Roche Investor Update. U.S. FDA grants Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab in primary progressive multiple sclerosis. www.roche.com/investors/updates/inv-update-2016-02-17.htm. Accessed 30 June 2016.
Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8:745–51.
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Evidence of remyelination with the Anti-LINGO-1 monoclonal antibody BIIB033 after acute optic neuritis. Presented at the American Academy of Neurology 67th annual meeting; 18–25 April 2015; Washington, DC.
Cadavid D, Phillips G, Dong-Si T, Tran J, Xu L. Efficacy and Safety of Anti LINGO-1 for the Treatment of Relapsing Forms of Multiple Sclerosis: Design of the Phase 2 SYNERGY Trial (P3.154). Neurology. 2014;82:1526–632X (10 Suppl).
Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435:620–7.
Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry. 2014;85:1116–21.
Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84:981–8.
Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72:159–69.
Burt RK, Balabanov R, Han X, Sharrack B, Morgan A, Quigley K, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015;313:275–84.
Pontikoglou C, Deschaseaux F, Sensebe L, Papadaki HA. Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev. 2011;7:569–89.
Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11:150–6.
Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr Stem Cell Res Ther. 2012;7:407–14.
Harris V, Vyshkina T, Chirls S, Sadiq S. Interim analysis of a phase I clinical trial investigating intrathecal administration of mesenchymal stem cell-neural progenitors in multiple sclerosis (P7.200). Neurology. 2015;84:1526–632X (14 Supplement).
Keyoung HM, Goldman SA. Glial progenitor-based repair of demyelinating neurological diseases. Neurosurg Clin N Am. 2007;18:93–104.
Goldman SA, Kuypers NJ. How to make an oligodendrocyte. Development. 2015;142:3983–95.
Goldman Lab, University of Rochester Medical Center. Lab focuses. www.urmc.rochester.edu/labs/goldman-lab/projects/glial_progenitor-based_cell_therapy_in_myelin_disease. Accessed 30 June 2016.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Klineova, S., Krieger, S. (2017). Emerging Therapies in Multiple Sclerosis. In: Miller, A. (eds) Handbook of Relapsing-Remitting Multiple Sclerosis. Adis, Cham. https://doi.org/10.1007/978-3-319-40628-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-40628-2_5
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-40626-8
Online ISBN: 978-3-319-40628-2
eBook Packages: MedicineMedicine (R0)